Gout

The rheumatology month in review features studies exploring ways to enhance care, an increased risk of adverse COVID-19 outcomes, and pegloticase plus methotrexate co-therapy for gout treatment.

Tarun Sharma, MD, discusses the overarching trends in treating gout, predictions for the future, and the stigma that often surrounds a gout diagnosis.

Leveraging data from a pair of commercial databases, a new study details the changes in febuxostat prescribing among patients with gout before, during, and after the FDA's addition of a Boxed Warning to prescribing information.

A retrospective analysis of nearly 150 patients with gouty arthritis in China provides further insight into the relationship between pathological ultrasound features and clinical signs and symptoms among this patient population.

An analysis of NHANES data is offering clinicians an overview of associations between hyperuricemia and gout with increased risk of mortality in patients with heart failure.

The pooled analysis showed the risk of all-cause dementia was decreased in patients with gout, particularly in patients receiving medication.

At month 12, response rate was significantly higher in patients receiving pegloticase and methotrexate when compared with concomitant placebo.

Obstructive sleep apnea was linked to an increased risk of gout in the female subgroup.

Women with gout were more likely to exhibit chronic kidney disease, heart failure, dementia, diabetes mellites, and obesity, among others, when compared with men.

The rheumatology month in review highlights a program developed by Janssen to support health equity, the increased risks pregnant women with rheumatic diseases face, and trends in fibromyalgia management.

NHANES data presented at EULAR 2023 offer insight into trends in the risk of mortality over a time period beginning in 1988 and lasting through 2016.

Data presented at EULAR 2023 details the factors that matter most to patients with gout when considering the continuation or discontinuation of urate-lowering therapy after achieving clinical remission.

A new-user, active comparator cohort study from EULAR 2023 suggests use of SGLT2 inhibitors could lower risk of recurrent gout flares in people with type 2 diabetes and gout compared to use of DPP-4 inhibitors.

After 12 weeks of treatment, the median sUA levels of patients with gout were reduced from 8.6 mg/dL to 3.6 mg/dL in the AR882 75 mg cohort and 5.0 mg/dL in the AR882 50 mg group.

Response rates in the DISSOLVE I and DISSOLVE II high-dose and low-dose groups receiving SEL-212 were significantly different from the placebo group.

Brian LaMoreaux, MD, discusses data from an analysis of the MIRROR trial examining the impact of pegloticase plus methotrexate on patient-reported outcomes and quality of life measures among patients with uncontrolled gout.

An analysis of patient-reported outcomes data from the MIRROR trial offers insight into the effects of pegloticase plus methotrexate on quality of life and various disease activity indices.

An analysis of NHANES data from 2011-2018 presented at EULAR 2023 offers an overview of the disproportionate growth in gout burden for Asian Americans relative to their White counterparts.

The findings suggest rural patients treated for gout had higher treatment adherence compared with urban patients.

Chronic tophaceous gout was demonstrated to be an independent risk factor linked to the development of colorectal cancer.

A Cox regression analysis showed a significant association between a gout diagnosis and subsequent breast cancer diagnosis in the total population.

Our latest case report from Brady Pregerson, MD, featuresa woman in her mid-60s with a history of Hashimoto’s thyroiditis treated with levothyroxine presenting to the hospital with 4-5 days of pain, swelling and redness on her left thumb.

Between 2011 and 2018, age- and sex-adjusted prevalence among Asian Americans doubled from 3.3% to 6.6%, which exceeded all other ethnic and racial groups.

A negative relationship between bone mineral density (BMD) and hyperuricemia in total, as well as in the L1, L2, and L3 lumbar vertebrae, was demonstrated in the multivariable-adjusted regression models.

Patients with intercritical gout had higher CXCL12 levels, IL-18, and IL-1β when compared with controls.

Although women with gout reported more severe symptoms and significantly worse illness perception and quality of life, they were given less information on ways to self-manage their condition.

No significant differences in the risk of myocardial infarction and other cardiovascular events were observed between patients with gout who received colchicine and those who did not.

Patients with cirrhosis had higher mortality rates, tophi, and gout flare.

An analysis of eGFR changes based on methotrexate use in the MIRROR trial offers new insight into the effects of pegloticase on renal function.

The evolving recognition of inflammation as a driver of cardiovaacular risk and has led some to speculate around a potential role for colchicine 0.5 mg, which has a PDUFA date in June 2023, for reducing risk in patients with ASCVD.